Novo Holdings participates in series B round at Belgian cancer firm
Biotech company Precirix raises EUR 80m from a consortium of investors, which included Novo Holdings.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Belgian biotech firm Precirix has finished a series B financing round raising EUR 80m, a press release reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Gilde Healthcare closes oversubscribed fund
For subscribers
Novo Holdings appoints new CFO
For subscribers
.jpg&w=384&q=75)
